{{위키데이터 속성 추적}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 452028402
| IUPAC_name = 8-[(3''R'')-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1''H''-purine-2,6-dione
| image = Linagliptin.svg
| width = 250

<!--Clinical data-->
| pronounce = {{IPAc-en|ˌ|l|ɪ|n|ə|ˈ|g|l|ɪ|p|t|ɪ|n}} {{respell|LIN|ə|GLIP|tin}}
| tradename = Tradjenta, Trajenta, Trazenta
| Drugs.com = {{drugs.com|monograph|linagliptin}}
| MedlinePlus = a611036
| licence_EU = yes
| DailyMedID = Linagliptin
| licence_US = Linagliptin
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_category =
| routes_of_administration = [[경구 투여]]
| ATC_prefix = A10
| ATC_suffix = BH05
| ATC_supplemental = 

| legal_AU = S4
| legal_AU_comment =<ref>{{웹 인용|url=http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-07/linagliptin|title=Linagliptin, tablet, 5 mg, Trajenta|website=Pharmaceutical Benefits Scheme (PBS)|date=July 2012|access-date=26 September 2014|archive-date=31 March 2015|archive-url=https://web.archive.org/web/20150331235220/http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-07/linagliptin|url-status=live}}</ref><ref>{{웹 인용| title=AusPAR: Linagliptin | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/resources/auspar/auspar-linagliptin-0 | access-date=9 April 2023}}</ref>
| legal_CA = Rx-only
| legal_CA_comment =<ref>{{웹 인용| title=Trajenta Product information | website=Health Canada | date=25 April 2012 | url=https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85612 | access-date=3 October 2022 | archive-date=27 September 2021 | archive-url=https://web.archive.org/web/20210927044057/https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85612 | url-status=live }}</ref>
| legal_UK = POM
| legal_UK_comment =<ref>{{웹 인용| title=Trajenta 5 mg film-coated tablets - Summary of Product Characteristics (SmPC) | website=(emc) | date=27 September 2021 | url=https://www.medicines.org.uk/emc/product/4762/smpc | access-date=3 October 2022 | archive-date=19 January 2022 | archive-url=https://web.archive.org/web/20220119184336/https://www.medicines.org.uk/emc/product/4762/smpc | url-status=live }}</ref>
| legal_US = Rx-only
| legal_US_comment =<ref name="Tradjenta FDA label">{{웹 인용| title=Tradjenta- linagliptin tablet, film coated | website=DailyMed | date=21 April 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f | access-date=3 October 2022 | archive-date=15 August 2022 | archive-url=https://web.archive.org/web/20220815101823/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f | url-status=live }}</ref>
| legal_EU = Rx-only
| legal_EU_comment =<ref>{{웹 인용| title=Trajenta EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta | access-date=11 February 2020 | archive-date=29 December 2019 | archive-url=https://web.archive.org/web/20191229222958/https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta | url-status=live }}</ref>
| legal_status = Rx-only

<!--Pharmacokinetic data-->
| bioavailability = ~30% ([[Cmax (pharmacology)|T<sub>max</sub>]] = 1.5 hours)
| protein_bound = 75–99% (concentration-dependent)
| metabolism = Minimal (~10% metabolized)
| metabolites = Pharmacologically inactive
| elimination_half-life = ~24 hours
| excretion = [[대변]] (80%), [[소변]] (5%)<ref name="Tradjenta FDA label" />

<!--Identifiers-->
| IUPHAR_ligand = 6318
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 668270-12-0
| PubChem = 10096344
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08882
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 237500
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 68610
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3X29ZEJ4R2
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09566
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8271879
| synonyms      = BI-1356

<!--Chemical data-->
| C=25 | H=28 | N=8 | O=2
| melting_point     = 202
| smiles = CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = LTXREWYXXSTFRX-QGZVFWFLSA-N
}}
<!-- Definition and medical uses -->
'''리나글립틴'''({{llang|en|linagliptin}})은 [[운동 (활동)|운동]] 및 [[당뇨병의 식이요법|식이요법]]과 함께 [[제2형 당뇨병]]([[제1형 당뇨병]]에 대해서는 아님)을 치료하는 데 사용되는 [[약물]]이다.<ref name="AHFS2019" /><ref name="Neumiller_2012">{{저널 인용|title=Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus|journal=The Annals of Pharmacotherapy|date=March 2012|volume=46|issue=3|pages=358–67|doi=10.1345/aph.1Q522|pmid=22318932|vauthors=Neumiller JJ|s2cid=207264493}}</ref> '''트라젠타'''({{llang|en|Trajenta 또는 Tradjenta}})라는 상품명으로 판매된다. 리나글립틴은 일반적으로 초기 치료에서 [[메트포르민]]이나 [[설포닐유레아]]보다 덜 선호된다.<ref name=AHFS2019/><ref name=BNF76/> 리나글립틴은 [[경구 투여|경구로 투여]]된다.<ref name=AHFS2019/>

일반적인 [[부작용]]으로는 [[코]]와 [[목]]의 [[염증]]이 있다.<ref name=AHFS2019/> 심각한 부작용으로는 [[혈관부종]], [[췌장염]], [[관절통]]이 포함될 수 있다.<ref name=BNF76/><ref name=AHFS2019/> [[임신]] 및 [[모유 수유]] 중 사용은 권장되지 않는다.<ref name=BNF76>{{서적 인용|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=680|edition=76}}</ref> 리나글립틴은 [[다이펩티딜 펩티데이스-4 저해제]]<ref name="AHFS2019" />로 [[인슐린]]의 생산을 증가시키고 [[이자 (해부학)|이자]]의 [[글루카곤]] 생산을 감소시키는 작용을 한다.<ref name=AHFS2019/>

리나글립틴은 2011년에 [[미국]],<ref>{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000TOC.cfm|title=Drug Approval Package: Tradjenta (linagliptin) Tablets NDA #201280|date=7 June 2011|website=U.S. [[Food and Drug Administration]] (FDA)|archive-url=https://web.archive.org/web/20220403111238/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000TOC.cfm|archive-date=3 April 2022|url-status=live|access-date=3 October 2022}}</ref> [[일본]], [[유럽연합]], [[캐나다]], [[오스트레일리아]]에서 의료용으로 승인되었다.<ref name=AHFS2019>{{웹 인용|title=Linagliptin Monograph for Professionals |url=https://www.drugs.com/monograph/linagliptin.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=6 April 2019 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406231038/https://www.drugs.com/monograph/linagliptin.html |url-status=live }}</ref><ref>{{웹 인용| title=10 years | website=Boehringer Ingelheim Limited | url=https://pro.boehringer-ingelheim.com/products/trajenta/10years#pre2011 | access-date=3 October 2022 | archive-date=3 October 2022 | archive-url=https://web.archive.org/web/20221003180613/https://pro.boehringer-ingelheim.com/products/trajenta/10years#pre2011 | url-status=live }}</ref> 2020년에 미국에서 293번째로 많이 처방된 약물이었으며, 처방 건수는 100만 건 이상이었다.<ref>{{웹 인용| title = The Top 300 of 2020 | url = https://clincalc.com/DrugStats/Top300Drugs.aspx | website = ClinCalc | access-date = 7 October 2022 }}</ref><ref>{{웹 인용| title = Linagliptin - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Linagliptin | access-date = 7 October 2022 }}</ref> 2021년 8월부터 리나글립틴은 미국에서 [[복제약]]으로 출시되었다.<ref>{{웹 인용| title=Linagliptin: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208335 | access-date=24 September 2021 | archive-date=25 September 2021 | archive-url=https://web.archive.org/web/20210925023535/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208335 | url-status=live }}</ref>

== 의료용 ==
리나글립틴은 제2형 당뇨병 환자인 성인의 혈당 조절을 개선하기 위해 [[당뇨병의 식이요법|식이요법]] 및 [[운동 (활동)|운동]]과 함께 치료제로 사용된다.<ref name="Tradjenta FDA label">{{웹 인용| title=Tradjenta- linagliptin tablet, film coated | website=DailyMed | date=21 April 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f | access-date=3 October 2022 | archive-date=15 August 2022 | archive-url=https://web.archive.org/web/20220815101823/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f | url-status=live }}</ref>

== 부작용 ==
리나글립틴은 심한 관절통을 유발할 수 있다.<ref name="Tradjenta FDA label" /><ref>{{웹 인용|title=DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain|url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain|website=U.S. Food and Drug Administration (FDA)|access-date=1 September 2015|date=28 August 2015|archive-date=13 December 2019|archive-url=https://web.archive.org/web/20191213203243/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain|url-status=live}}</ref>

== 작용 메커니즘 ==
리나글립틴은 [[다이펩티딜 펩티데이스-4 저해제]](DPP-4 저해제)라고 불리는 약물 종류에 속한다.<ref name="Tradjenta FDA label" />

== 명칭 ==
리나글립틴은 [[국제일반명]](INN)이다.<ref name="INN">{{웹 인용|title=International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 61 |url=https://www.who.int/medicines/publications/druginformation/innlists/RL61.pdf |publisher=World Health Organization |access-date=10 November 2016 |page=66 |archive-date=3 October 2020 |archive-url=https://web.archive.org/web/20201003141721/https://www.who.int/medicines/publications/druginformation/innlists/RL61.pdf |url-status=live }}</ref> 상품명은 '''트라젠타'''({{llang|en|Trajenta 또는 Tradjenta}})이다.<ref>{{웹 인용| title=Linagliptin: medicine to treat type 2 diabetes | website=NHS UK| date=25 March 2022|url=https://www.nhs.uk/medicines/linagliptin/ | access-date=21 November 2022}}</ref>

== 같이 보기 ==
* [[엠파글리플로진/리나글립틴]]
* [[제2형 당뇨병]]
* [[글리피지드]]
* [[항당뇨병제]]
* [[설포닐유레아]]
* [[메트포르민]]

== 각주 ==
{{각주}}

== 외부 링크 ==
{{위키공용분류}}
* {{웹 인용| url = https://druginfo.nlm.nih.gov/drugportal/name/linagliptin | publisher = U.S. National Library of Medicine| work = Drug Information Portal | title = Linagliptin }}

[[분류:알카인 유도체]]
[[분류:베링거 인겔하임]]
[[분류:다이펩티딜 펩티데이스-4 저해제]]
[[분류:일라이 릴리 앤드 컴퍼니의 제품]]
[[분류:피페리딘]]
[[분류:퀴나졸린]]
[[분류:잔틴]]